Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
Walmart | BUY $90 | ― | -9.00% | Assigned | Barclays Reviews Walmart (WMT) EarningsBarclays analyst Karen Short reiterated an Overweight rating and $78.00 price target on Walmart (NYSE: WMT). | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $95 | ― | 25.20% | Upgraded | ||||
Taysha Gene Therapies | BUY $5 | ― | -0.10% | Reiterated | Buy Rating for Taysha Gene Therapies Due to Safer Administration Method and Lower Viral Dose | ||||
Zevra Therapeutics | BUY $17 | ― | -5.90% | Reiterated | Zevra Therapeutics Gains Buy Rating Amid Successful MIPLYFFA Launch and Strong Market Response | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $81→$86 | ― | 6.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $46 | ― | 30.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $70 | ― | 8.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $181 | ― | 22.40% | Reiterated | ||||
Gulfport Energy | BUY $205 | ― | -7.70% | Reiterated | KeyBanc Sticks to Its Buy Rating for Gulfport Energy (GPOR) | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125 | ― | 9.00% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $448 | ― | 5.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $646→$675 | ― | 1.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $43 | ― | 1.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $110 | ― | 9.40% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $180 | ― | 15.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $175 | ― | 24.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $60 | ― | 10.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $300 | ― | 14.80% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $450 | ― | 15.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $30 | ― | 3.90% | Reiterated | ||||
Kura Oncology | BUY $28 | ― | -17.50% | Reiterated | Strategic Partnership with Kyowa Kirin Positions Kura Oncology for Leadership in AML Menin Inhibitor Market | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $30 | ― | 5.60% | Upgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $15 | ― | 5.60% | Upgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $250 | ― | 15.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $48 | ― | 5.50% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $22→$18 | ― | 2.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $14 | ― | 2.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $165→$170 | ― | 1.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $60 | ― | 4.10% | Reiterated | ||||
Vertex Pharmaceuticals | HOLD $486 | ― | -1.60% | Reiterated | Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $400 | ― | 1.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $205 | ― | 26.50% | Assigned | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $113 | ― | 10.30% | Reiterated | ||||
Fluence Energy | BUY $27→$25 | ― | -4.20% | Reiterated | Fluence Energy price target lowered to $25 from $27 at Roth MKM | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $180 | ― | 23.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $25→$28 | ― | 17.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $68 | ― | 2.90% | Reiterated | ||||
Amgen | BUY $380 | ― | -2.00% | Reiterated | Jefferies Sticks to Their Buy Rating for Amgen (AMGN) | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $689 | ― | 10.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $150 | ― | 1.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $122 | ― | 10.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $19.3→$20.2 | ― | 47.60% | Upgraded | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $275 | ― | 5.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $138→$142 | ― | 4.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $64→$78 | ― | 0.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $60→$70 | ― | 2.40% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $180 | ― | 12.70% | Assigned | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $350→$390 | ― | 2.40% | Reiterated | ||||
xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $130 | ― | 10.70% | Assigned | ||||
AFLAC | HOLD $107→$110 | ― | -0.50% | Reiterated | Morgan Stanley Sticks to Their Hold Rating for AFLAC (AFL) |